Avadomide is a cereblon E3 ligase modulator drug that stimulates T-cell immune synapse while increasing PD-L1 expression, it triggers IFN-driven T-cell responses and converts noninflamed CLL tumors into CD8+ T cell-inflamed ones, making CLL sensitive to PD-1/PD-L1 immunotherapy. This evidence concerns the gene PDCD1 and B-cell chronic lymphocytic leukemia.